

# Contents

<b>Chapter 1</b>	<b>Introduction and General Aspects of Risk Assessment</b>	<b>1</b>
	<i>Timothy C. Marrs and Robert L. Maynard</i>	
1.1	History of Regulation in the European Union (EU)	1
1.2	Philosophical Aspects of Risk	2
1.3	Types of Regulatory Regime	2
1.4	Quality of Data	3
1.4.1	Proprietary Data <i>Versus</i> Studies in the Peer-reviewed Literature	3
1.4.2	Proprietary Data	4
1.4.3	Data from the Peer-reviewed Literature	6
1.4.4	Human Data	8
1.5	Expertise	9
1.6	General Aspects of Risk Assessment	10
1.6.1	Derivation of Standards	11
1.6.2	Standards	13
1.6.3	Risk Management	16
1.7	Conclusions	16
	Acknowledgements	17
	References	17
<b>Chapter 2</b>	<b>Regulation of Medicinal Products for Human Use in the European Union</b>	<b>22</b>
	<i>Henry E. Stemplewski</i>	
2.1	Introduction	22
2.2	What Are Medicinal Products for Human Use?	23

2.3	Background to the Legislation	23
2.4	EU Legislation	24
2.5	Legislation: Differences Between Regulations, Directives and Guidelines	25
2.6	The EU Regulatory System for Medicinal Products	26
2.7	European Medicines Agency (EMA): Role, Tasks and Functioning	27
2.8	EMA: Scientific Committees	28
2.8.1	Committee for Medicinal Products for Human Use (CHMP)	28
2.8.2	The Pharmacovigilance Risk Assessment Committee (PRAC)	30
2.8.3	The Committee for Orphan Medicinal Products (COMP)	31
2.8.4	The Committee on Herbal Medicinal Products (HMPC)	31
2.8.5	The Committee for Advanced Therapies (CAT)	31
2.8.6	The Paediatric Committee (PDCO)	32
2.9	Composition of Committees	33
2.10	Scientific Guidelines	34
2.11	Marketing Authorisation Procedures	34
2.11.1	Centralised Procedures	34
2.11.2	Support for Early Access to Medicines	35
2.11.3	Accelerated Assessment	36
2.11.4	Conditional Marketing Authorisation	36
2.11.5	Exceptional Circumstances Authorisation	37
2.11.6	Compassionate Use	38
2.11.7	PRIME (PRIority MEDicines) Scheme	38
2.12	Decentralised Procedure (DCP)	39
2.13	Mutual Recognition Procedure (MRP)	40
2.14	National Authorisation Procedures	40
2.15	Special Procedures	40
2.15.1	Article 58 Applications	40
2.15.2	Compassionate Use	41
2.16	Referral Procedures	41
2.17	Data Submission on Medicines	41
2.18	Scientific Assessments	42
2.19	Adopting a Committee Opinion or Recommendation	43
2.20	Transparency	43
2.21	European Public Assessment Reports (EPARs)	43
2.22	Standing and Temporary Working Parties	44
2.22.1	The Safety Working Party (SWP)	46

2.22.2	The Scientific Advice Working Party (SAWP)	46
2.22.3	The Biologics Working Party (BWP)	47
2.22.4	The Joint Committee for Medicinal Products for Human Use/Committee for Medicinal Products for Veterinary Use Quality Working Party (QWP)	47
2.22.5	Healthcare Professionals' Working Party (HCPWP)	48
2.22.6	Patients' and Consumers' Working Party (PCWP)	48
2.23	Safety Monitoring of Medicines	48
2.24	Inspections	49
2.25	The Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)	49
2.26	Regulatory Rules for Specific Types of Medicinal Products or Investigations	50
2.26.1	Clinical Trials	50
2.26.2	Orphan Medicinal Products	52
2.26.3	Paediatric Medicines	53
2.26.4	Geriatric Medicines	56
2.26.5	Advanced Therapy Medicinal Products (ATMPs)	56
2.26.6	Biological Medicinal Products and Similar Biological Product	57
2.26.7	Generic Medicines	58
2.26.8	Hybrid Medicines	59
2.26.9	Herbal Medicines	59
2.26.10	Homeopathic Medicines	60
2.26.11	Non-prescription Medicines	61
2.27	Innovation in Medicines	62
2.28	Scientific Advice	63
2.29	Conclusion	64
	References	64
<b>Chapter 3</b>	<b>Regulatory Toxicology for Human Medicines in the European Union</b>	<b>72</b>
	<i>Henry E. Stemplewski</i>	
3.1	Introduction	72
3.2	Life Cycle of a Typical Human Medicine	73
3.3	Clinical Trials	74
3.4	Guidelines	75
3.5	Scientific Flexibility in Interpretation of Regulatory Guidelines	76
3.6	ICH Guidelines	76

3.6.1	Safety Guidelines	78
3.6.2	Multidisciplinary Guidelines	79
3.7	The Common Technical Document (CTD)	79
3.8	CHMP (EU) Guidelines	82
3.9	Purpose of Non-clinical Testing	83
3.10	Predictive Value of Animal Studies in the Risk Assessment of Human Medicines	84
3.10.1	Use of Recovery Phase Animals	85
3.10.2	Statistical Considerations	85
3.11	3Rs (Replacement, Reduction and Refinement) in the Regulatory Testing of Human Medicinal Products	86
3.12	Study Design in Regulatory Toxicology Studies	87
3.13	Dose Selection for Non-clinical Testing	87
3.14	Biological Medicinal Products	89
3.15	Interpretation of Data	91
3.16	Weight of Evidence Approach in the Interpretation of Data	92
3.17	Types of Non-clinical Studies in Regulatory Toxicology	93
3.17.1	Pharmacodynamics	95
3.17.2	Secondary Pharmacodynamics	95
3.17.3	Safety Pharmacodynamics	96
3.17.4	Pharmacodynamic Drug Interactions	96
3.17.5	Pharmacokinetics	96
3.17.6	The Role of Pharmacokinetics in the Drug Development Process	99
3.17.7	Toxicokinetics	99
3.17.8	Single Dose/Acute Toxicity Studies	100
3.17.9	Repeated Dose Toxicity	100
3.17.10	Genotoxicity	103
3.17.11	Carcinogenicity	106
3.17.12	Reproductive Toxicity	111
3.17.13	Juvenile Animal Toxicity	112
3.17.14	Local Tolerance	113
3.17.15	Sensitising Potential	114
3.17.16	Photosafety Evaluation	114
3.17.17	Immunotoxicity	115
3.17.18	Antigenicity	115
3.17.19	Dependence Potential	116
3.17.20	Impurities	116
3.17.21	Environmental Risk Assessment (ERA)	117
3.18	Risk Assessment: the Integration of Clinical and Non-clinical Data	119
3.18.1	Conclusion	120
3.18.2	General Aspects	121
3.19	Good Laboratory Practice (GLP)	122

<i>Contents</i>	xiii
3.20 Conclusion	122
References	123
<b>Chapter 4 Pharmacovigilance for Authorised Human Medicinal Products in the European Union</b>	<b>129</b>
<i>Brian D. Edwards and Shelley Gandhi</i>	
4.1 The Global System for Pharmacovigilance	129
4.2 Development of the Current EU Pharmacovigilance System for Authorised Medicines	135
4.3 Re-organisation of the EU Regulatory System Concerning Pharmacovigilance	138
4.4 Quality Management, Compliance and Inspections	142
4.5 Pharmacovigilance Obligations of Being an EU Marketing Authorisation Holder	143
4.6 Risk Management	146
4.7 Reporting Requirements for Individual Cases and Periodic Reports	149
4.8 Reporting Requirements for Periodic Reports	153
4.9 Signal Management	154
4.10 Post-authorisation Safety Studies (PASS)	155
4.11 What Would an Ideal Global Pharmacovigilance System Look Like for a Company?	157
Further Recommended Reading	158
References	158
<b>Chapter 5 Veterinary Medicinal Products</b>	<b>163</b>
<i>Kevin N. Woodward</i>	
5.1 Introduction	163
5.2 Pre-clinical Safety	166
5.3 Consumer Safety	166
5.3.1 Establishment of MRLs in the EU	167
5.3.2 Elaboration of MRLs	173
5.3.3 The Joint FAO/WHO Expert Committee on Food Additives (JECFA)	176
5.3.4 Practical Uses of MRLs	177
5.3.5 Residues Surveillance	180
5.3.6 Residues Avoidance	186
5.4 User Safety	188
5.4.1 The Assessment Process	190
5.4.2 Hazard Identification and Assessment	190
5.4.3 Exposure Assessment	192
5.4.4 Biological Monitoring	198
5.4.5 Risk Assessment	199

5.4.6 Risk Management	201
5.4.7 Risk Communication	202
5.5 Conclusions	203
Acknowledgements	205
References	205
<b>Chapter 6 Pharmacovigilance for Veterinary Medicinal Products</b>	<b>243</b>
<i>Kevin N. Woodward</i>	
6.1 Introduction	243
6.2 Regulation of Veterinary Medicinal Products in the EU	245
6.2.1 Historical Context	245
6.2.2 The Current Situation – up to 2017	246
6.3 Pharmacovigilance for VMPs	247
6.3.1 Requirements of Directive 2001/82/EC	247
6.3.2 Requirements of Regulation (EC) No 2309/93	256
6.3.3 Revision in 2004 and Onwards	257
6.3.4 Good Pharmacovigilance Practices	260
6.4 Some Findings from Pharmacovigilance Activities	261
6.4.1 Pharmacovigilance in the UK	262
6.4.2 Data Available from the EMA	264
6.5 Assessment of Adverse Reaction Reports	269
6.5.1 Temporal Relationships	269
6.5.2 Dechallenge/Rechallenge	270
6.5.3 Anatomical Site of the Reaction	270
6.5.4 Time Course of the Reaction	270
6.5.5 Previous Adverse Drug Reactions	270
6.5.6 Type of Adverse Reaction	271
6.5.7 Drug–Drug Interactions	271
6.5.8 Neonatal and Geriatric Patients	271
6.5.9 Test Results	271
6.5.10 Use of Pharmacology and Toxicology Data	271
6.5.11 Algorithms for Causality in Pharmacovigilance	272
6.5.12 Consideration of Expectedness	278
6.6 Some Examples of Adverse Reactions to Veterinary Medicinal Products	283
6.6.1 Adverse Reactions in Animals	283
6.6.2 Adverse Reactions in Humans	288
6.7 Conclusions	302
References	302

<b>Chapter 7</b>	<b>Animal Feed Additives</b>	<b>355</b>
	<i>Derek W. Renshaw</i>	
7.1	Animal Feedstuffs	355
7.2	Feed Additives	356
7.2.1	Regulatory Framework	356
7.3	The European Food Safety Authority	360
7.4	The Committees	361
7.4.1	The Scientific Committee on Animal Nutrition (SCAN)	361
7.4.2	The FEEDAP Panel and Its Working Groups	361
7.4.3	Other EFSA Panels Working on Animal Feed	364
7.4.4	The Standing Committee on Plants, Animals, Food and Feed (SCoPAFF)	366
7.4.5	Other Bodies Whose Work May Affect the Use of Feed Additives in the EU	367
7.5	Evaluation of the Safety of Feed Additives	367
7.5.1	Mandate from the Commission	367
7.5.2	Sources of Data	368
7.5.3	Drafting an Opinion	368
7.5.4	Quality and Reliability of Data	369
7.5.5	Target Animal Safety	370
7.5.6	Consumer Safety	372
7.5.7	User Safety	384
7.5.8	Environmental Safety	387
7.5.9	Post-market Monitoring	389
7.6	Risk Communication	389
7.7	Challenges for the Future	390
7.7.1	The PROMETHEUS Project	390
7.7.2	Uncertainty	390
7.7.3	Weight of Evidence	391
7.7.4	Mixtures	391
7.7.5	Ultra-fine Particles	393
7.8	Future Amendments to Legislation	393
7.9	Concluding Remarks	394
	References	395
<b>Chapter 8</b>	<b>Regulatory Toxicology of Pesticides: Concepts</b>	<b>402</b>
	<i>V. Ritz and Roland A. Solecki</i>	
8.1	Introduction	402
8.2	Risk Assessment of Pesticides	403
8.2.1	Pesticidal Active Substances	404
8.2.2	Plant Protection Products	410
8.2.3	Biocidal Products	414
8.2.4	Risk Assessment	418

8.3	Future Trends in Regulatory Toxicology	418
8.3.1	New Methodologies	418
8.3.2	Development of Test Guidelines	419
8.3.3	Cumulative Risk Assessment	422
8.3.4	Metabolites	426
8.3.5	Micro-organisms	427
	List of Abbreviations	428
	Acknowledgements	429
	References	430
<b>Chapter 9</b>	<b>Legal Background and Procedures on Pesticides</b>	<b>439</b>
	<i>Bernd Stein, Stefanie Rotter and Vera Ritz</i>	
9.1	Introduction	439
9.2	Plant Protection Products	440
9.2.1	Approval of Active Substances	441
9.2.2	Authorisation of Plant Protection Products	445
9.2.3	Setting of Maximum Residue Levels	449
9.3	Biocidal Products	454
9.3.1	Approval of Active Substances	456
9.3.2	Authorisation of Biocidal Products	459
9.4	Regulation on Classification, Labelling and Packaging	463
	List of Abbreviations	464
	Acknowledgements	465
	References	465
<b>Chapter 10</b>	<b>REACH</b>	<b>468</b>
	<i>David J. Andrew and Siân L. Wright-Williams</i>	
10.1	Introduction	468
10.2	The Aims of REACH	469
10.2.1	Substance Identification	469
10.2.2	Substance Registration	469
10.2.3	Substance Evaluation	470
10.2.4	Substance Authorisation	470
10.2.5	Substance Restriction	471
10.3	REACH Data Requirements	471
10.3.1	Substance Data Requirements	471
10.3.2	Intermediate Data Requirements	471
10.3.3	General Principles	471
10.3.4	Data Requirement Waiving	472
10.3.5	Annex XI Waivers	472
10.3.6	Annex III Criteria	474



10.3.7	Vertebrate Animal Testing and Alternative Methods Under REACH	474
10.3.8	The 'Testing Proposal' Concept	474
10.3.9	Read-across	475
10.4	REACH Toxicological Data Requirements	478
10.4.1	Skin Irritation/Corrosion and Eye Irritation	479
10.5	Data Compilation and Assessment	493
10.5.1	IUCLID	493
10.5.2	Key, Supporting and Weight of Evidence Studies	493
10.5.3	Assessment of Data Reliability	494
10.6	Toxicological Data and Risk Assessment	495
10.6.1	DNEL Derivation	495
10.6.2	The Chemical Safety Report	497
10.6.3	Safety Data Sheet	498
10.7	Conclusion	499
	References	499
<b>Chapter 11</b>	<b>Cosmetic Products</b>	<b>505</b>
	<i>Tracey A. Finlay and David J. Andrew</i>	
11.1	Introduction	505
11.2	General Regulatory Aspects	506
11.2.1	Definition of a Cosmetic Product	506
11.2.2	The Cosmetic Product Safety Report	507
11.2.3	The Safety Assessor	507
11.2.4	The Scientific Committee on Consumer Safety	507
11.2.5	Restrictions on Ingredients Used in Cosmetic Products	509
11.3	Safety Assessment of Cosmetic Products	512
11.3.1	Microbiological and Stability Testing	512
11.3.2	Ingredient Toxicological Profiles	512
11.3.3	Cosmetic Products and Animal Testing	513
11.3.4	Toxicological Data Requirements	514
11.3.5	Final Conclusion on Product Safety	525
11.3.6	Use of the Product	526
11.3.7	Cosmetic Ingredients and Product Exposure	526
11.3.8	Impact of Impurities and Traces	529
11.3.9	Assessment of Product Packaging	531
11.3.10	Post-marketing Surveillance	531
11.4	Conclusion	532
	References	532

<b>Chapter 12</b>	<b>Regulation of Air Quality in the European Union</b>	<b>539</b>
	<i>Robert L. Maynard and Martin L. Williams</i>	
12.1	Introduction	539
12.2	European Legislation	541
12.2.1	The Need for Standards for Ambient Concentrations of Air Pollutants	541
12.2.2	Setting Standards for Air Pollutants	544
12.2.3	Conclusions from Studies of the Effects of Ambient Particles	545
12.2.4	Setting EU Limit Values	547
12.2.5	Is There a Better Way of Regulating Ambient Air Pollutants: Is There a Better Sort of “Standard”?	552
12.2.6	Regulating Air Pollutants Within a Multi-national Confederation	553
12.3	Conclusions	554
	References	555
<b>Chapter 13</b>	<b>Occupational Toxicology in the European Union</b>	<b>557</b>
	<i>Ian C. Dewhurst</i>	
13.1	Introduction	557
13.2	Exposures	558
13.3	History	559
13.4	Occupational Exposure Limits (OELs)	559
13.4.1	Setting of Occupational Exposure Limits at EU Level	561
13.4.2	SCOEL Working Practices	562
13.5	DNELs	569
13.6	Classification and Labelling	570
13.7	Protective Equipment	572
13.8	Conclusion	573
	Further Reading	573
	References	574
<b>Chapter 14</b>	<b>Food Additives</b>	<b>577</b>
	<i>Peter J. Aggett</i>	
14.1	Introduction	577
14.2	Development of Current Regulation	578
14.2.1	Harmonisation	578
14.2.2	Creation of the Internal Market	578
14.2.3	The European Food Safety Authority and Public Health Protection	579
14.2.4	Food Improvement Agents Regulations	579

14.3	Current Regulations and Legislative Procedure Within the European Union	580
14.3.1	Definition of a Food Additive	581
14.4	Function of Food Additives	582
14.4.1	Functional Classes of Food Additives	582
14.4.2	The Union List of Additives and Their Conditions of Use	585
14.4.3	E Number Classification	586
14.5	The Use of Food Additives	586
14.5.1	Foodstuffs in Which Food Additives May Not be Used	587
14.5.2	Traditional Foods	589
14.5.3	Food Categories in Which Food Additives May be Used	589
14.5.4	Levels of Use of Food Additives (Regulation (EC) No 1333/2008, Article 11)	590
14.5.5	Purity and Specifications of Food Additives	590
14.5.6	Carry-over Principle	591
14.6	Labelling	592
14.7	Surveillance and Monitoring of Use of Food Additives	593
14.8	Reauthorisation of Additives	593
14.9	Risk Assessment of Food Additives	593
14.9.1	General Points	593
14.9.2	Procedure for Risk Assessment of Food Additives	594
14.9.3	Toxicology Studies	595
14.9.4	Exposure Assessment	597
14.10	Application Procedure	598
14.11	Risk Management Information for the Evaluation of Food Additives	598
14.12	Future Developments	599
	Further Reading	599
	References	600

<b>Appendix I</b>	<b>604</b>
-------------------	------------

<b>Subject Index</b>	<b>606</b>
----------------------	------------